Clinical trials: Leucovorin
Tongue Cancer, Chemotherapy Effect
A Study of Tongue Conservation Surgery for Oral Tongue Cancer
This is an open-label, non-comparative phase II clinical trial to assess efficacy and safety of tongue conservation treatment with sequential induction chemotherapy, tongue conservation surgery and postoperative concurrent…
- Conditions
- Tongue Cancer, Chemotherapy Effect, Surgery
- Trial name
- NCT03161548
- Testing
- Induction chemotherapy, Tongue conservation surgery, postoperative CCRT
- Volunteers
- 23 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Colorectal Cancer
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
The purpose of this study was to determine the activity of two doses of robatumumab (SCH 717454, MK-7454) in participants with relapsed or recurrent colorectal cancer.
- Trial name
- NCT00551213
- Testing
- Robatumumab, Irinotecan, Cetuximab
- Volunteers
- 67 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Neoplasms, Neoplasm Metastasis
Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer
The primary objective of the study is to estimate the progression-free survival rate at 12 months for the two arms of the study.
- Trial name
- AFFIRM (NCT00851084)
- Testing
- aflibercept, oxaliplatin, 5-FU
- Where
- 37 sites in Australia, Germany and 5 more
- Volunteers
- 268 people
- Sponsor
- Sanofi
Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma
Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell Carcinoma
Oxaliplatin is a platinum analogue that has significant antitumor activity with better tolerability than cisplatin. The objective of the study is to evaluate the safety and activity of leucovorin and 5-fluorouracil and leucovorin…
- Trial name
- NCT01467921
- Testing
- oxaliplatin
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Samsung Medical Center
Pancreatic Cancer
Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer
This multicentric open-label trial will compare the efficacy and safety of stereotactic body radiation therapy (SBRT) followed by NALIRIFOX (5-fluorouracil, leucovorin, irinotecan liposome injection and oxaliplatin) vs NALIRIFOX…
- Trial name
- NCT06259058
- Testing
- Irinotecan liposome injection, Oxaliplatin, 5-Fluorouracil
- Volunteers
- 96 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Neoplasms Malignant
Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
To observe and evaluate the efficacy and safety of irinotecan liposome (II) combined with 5-fluorouracil(5-FU), calcium leucovorin(LV), and bevacizumab in the treatment of metastatic colorectal cancer.
- Trial name
- NCT06643793
- Testing
- Irinotecan liposome (ll) + 5-FU/LV + bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Liver Metastasis Colon Cancer, Synchronous Neoplasm
Surgery Outcome Treated by Neo-adjuvant Combination of Oxaliplatin, Irinotecan, Folinic Acid and Fluorouracil (FOLFOXIRI) Regimen in Synchronous Liver Limited Metastasis Colorectal Cancer
This single arm study aims to evaluate the rate of conversion therapy in patients with unresectable liver-limited metastatic colorectal cancer (mCRC) using FOLFOXIRI neoadjuvant regimen and to assess the other outcome including…
- Trial name
- NCT05362825
- Testing
- Neo-adjuvant Chemotherapy FOLFOXIRI Regimen, synchronous resection surgery
- Where
- Vietnam
- Volunteers
- 89 people
- Sponsor
- Cho Ray Hospital
Lymphoma
Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- ALCL 99 (NCT00006455)
- Testing
- cyclophosphamide, cytarabine, dexamethasone
- Where
- 10 sites in Austria, Belgium and 8 more
- Volunteers
- 885 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
Colorectal Cancer, Liver Metastasis
Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
To evaluate the safety and efficacy of sintilimab combined with regorafenib and HAIC in patients with colorectal liver metastasis who failed second-line therapy
- Trial name
- NCT05524155
- Testing
- HAIC, Sintilimab, Regorafenib
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer Stage II
First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer
Bevacizumab in combination with chemotherapy represents a standard of care for first-line treatment in patients with advanced colorectal cancer.
- Trial name
- CENTRAL (NCT01853813)
- Testing
- Bevacizumab and FOLFIRI
- Where
- 13 sites in Italy
- Volunteers
- 85 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Potentially Resectable Hepatocellular Carcinoma
A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma
This is a single term, open label, single Center, Phase II Trial. The study is to explore the efficacy and safety of FOLFOX-HAIC combined with Lenvatinib and Envolizumab in the treatment of patients with potentially resectable…
- Trial name
- NCT06143579
- Testing
- FOLFOX-HAIC+Lenvatinib+Envolizumab
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University
Esophagogastric Adenocarcinoma
Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma
This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity of a first-line therapy consisting of induction chemotherapy plus pembrolizumab (12 weeks of mod.
- Trial name
- NCT05268510
- Testing
- Pembrolizumab, Olaparib, mFOLFOX-6
- Where
- Germany
- Volunteers
- 31 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of low-dose bevacizumab plus atezolizumab combined with transarterial chemoembolization followed by hepatic arterial infusion…
- Conditions
- Hepatocellular Carcinoma, Atezolizumab Plus Bevacizumab, Transarterial Chemoembolization
- Trial name
- NCT07543510
- Testing
- TACE-HAIC + Atezolizumab + Low-dose Bevacizumab
- Volunteers
- 38 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Peritoneal Carcinomatosis
Intraperitoneal Docetaxel in Combination With mFOLFOX6 for Gastric Cancer Patients With Peritoneal Carcinomatosis
This is a single-center, open-label, non-randomized, uncontrolled Phase 1 study of intraperitoneal docetaxel in combination with systemic mFOLFOX6 for patients who have gastric cancer with gross peritoneal carcinomatosis (GC-PC).
- Trial name
- NCT04583488
- Testing
- Intraperitoneal docetaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Johns Hopkins University
Cancer
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
This study will aims to determine the maximum tolerated dose of CGC-11047 when used in individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or cisplatin or 5-flurouracil or sunitinib in one of 7…
- Trial name
- NCT00705874
- Testing
- CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 172 people
- Sponsor
- Progen Pharmaceuticals
Autism Spectrum Disorder, Language Disorders
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves language as well as the…
- Trial name
- NCT04060017
- Testing
- Levoleucovorin Calcium
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Southwest Autism Research & Resource Center
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil [5-FU] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine)…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Trial name
- NCT06998940
- Testing
- Biospecimen Collection, Computed Tomography, Fluorouracil
- Where
- 274 sites in United States
- Volunteers
- 94 people
- Sponsor
- SWOG Cancer Research Network
B-cell Lymphoma
Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
Multicenter prospective open-label non-randomised phase I/II study in patients with relapsed or refractory CD20-positive aggressive lymphomas Phase I: Dose escalation of methotrexate and cytarabine (days 1, 8 and 15 of each…
- Trial name
- LeMLAR (NCT01788189)
- Testing
- Lenalidomide
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- University Hospital, Essen
Pancreatic Cancer
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
This is an open-label, phase 2 non-comparative study to assess the safety, tolerability, and preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients not previously treated for metastatic…
- Trial name
- NCT02551991
- Testing
- nal-IRI, 5 fluorouracil, Leucovorin
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 56 people
- Sponsor
- Ipsen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.